Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known whether fluorouracil and mitomycin plus radiation therapy is more effective than fluorouracil and cisplatin plus radiation therapy for anal cancer.

Official Title

Phase III Randomized Study of Fluorouracil and Mitomycin With Concurrent Radiotherapy Versus Fluorouracil and Cisplatin With Concurrent Radiotherapy in Patients With Anal Canal Carcinoma

Conditions

– stage II anal cancer- stage III anal cancer- squamous cell carcinoma of the anus- cloacogenic carcinoma of the anus- basaloid carcinoma of the anus

Study Type

Interventional

Study Design

Treatment

Further Details

PURPOSE: Randomizedphase III trial to compare the effectiveness of fluorouracil and mitomycin plus radiation therapy with that of fluorouracil and cisplatin plus radiation therapy in treating patients who have stage II or stage III anal cancer. OBJECTIVES:Compare the initial and total local and distant failure rates in patients with anal canal cancer treated with either fluorouracil (5-FU) plus mitomycin concurrently with radiotherapy or 5-FU plus cisplatin followed by 5-FU plus cisplatin concurrently with radiotherapy. Identify any differences in local control and colostomy rates at 2 years in patients treated with these regimens. Determine any difference in colostomy free, disease free, or overall survival in patients treated with these regimens. Compare the toxic effects of these regimens in these patients. Evaluate the prognostic effects of tumor markers P53 overexpression, human papilloma virus status, and enzyme HAP1 in patients treated with these regimens. OUTLINE: This is a randomized study. Patients are stratified according to gender, nodal status (positive vs negative), and primary tumor size (greater than 2 cm to 5 cm vs greater than 5 cm). Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive fluorouracil (5-FU) IV continuously over 96 hours beginning on days 1 and 29 and mitomycin IV on days 1 and 29 with concurrent radiotherapy. Arm II: Patients receive induction chemotherapy comprising 5-FU IV continuously over 96 hours beginning on days 1, 29, 57, and 85 and cisplatin IV over 1 hour on days 1, 29, 57, and 85. Beginning on day 57, patients receive concurrent radiotherapy. In both arms, radiotherapy is administered daily, 5 days a week, for 5-6.5 weeks. Patients with T3, T4, or N+ lesions or T2 lesions with residual disease receive additional radiotherapy to a reduced field. Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.PROJECTED ACCRUAL: A total of 650 patients will be accrued for this study within 5 years.

Study Start

Eligibility & Criteria

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both Criteria DISEASE CHARACTERISTICS:Histologically confirmed primary squamous, basaloid, or cloacogenic carcinoma of the anal canal, other than carcinoma in situ T2-4, Any N, M0 (stage II or III) No local or regional recurrence after local excision or abdominal peritoneal resection PATIENT CHARACTERISTICS: Age:18 and over Performance status:Karnofsky 60-100% Life expectancy:Not specified Hematopoietic:WBC at least 4,000/mm^3 Absolute neutrophil count at least 1,800/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 10 g/dL Hepatic:Bilirubin less than 1.4 mg/dL Renal:Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 80 mL/min Cardiovascular:No uncompensated heart disease No uncontrolled high blood pressure Other:No AIDS No active systemic infection No uncontrolled diabetes No other prior malignancy within the past 5 years except nonmelanoma skin cancer No mental condition that would preclude study participation Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy:Prior epoetin alfa allowed in lieu of blood transfusions Chemotherapy:At least 5 years since prior chemotherapy Endocrine therapy:Not specified Radiotherapy:At least 5 years since prior radiotherapy Surgery:No prior surgery of anal canal except for biopsy of study site

Total Enrolment

Contact Details